Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Constellation Pharmaceuticals has signed a strategic agreement with Genentech to discover and develop treatments for cancer and other diseases, based on the science of epigenetics and chromatin biology.
Subscribe to our email newsletter
As per the collaboaration, Constellation will receive committed funding of $95m, comprising an upfront payment and research funding for a three-year collaboration period.
Constellation will also be entitled for substantial development and commercialization milestone payments, besides double-digit royalties on commercial sales of multiple products by Genentech.
Constellation is believed to retain exclusive development and commercialization rights to selected programs arising from the collaboration, for which payments would be due to Genentech upon the successful commercialization of such products.
Genentech’s option to acquire Constellation includes the BET and EZH2 programs as well as other programs outside the collaboration scope.